GRIFOLS | GRF - Cash And Equivalent


GRIFOLS reported EUR801M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amadeus IT EUR 975.6M 7.4M Dec/2025
Amarin USD 131.06M 3.6M Mar/2026
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Cie Automotive EUR 486.62M 9.22M Dec/2024
Demant DKK 1.33B 188M Dec/2025
Ence Energia y Celulosa EUR 249.6M 19.18M Sep/2025
Essilor EUR 3.54B 758M Dec/2025
Ferrovial EUR 4.24B 1.41B Dec/2025
Fresenius EUR 1.31B 81M Dec/2025
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Inditex EUR 5.28B 675M Dec/2025
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Philips EUR 2.79B 882M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024
Viscofan EUR 62.79M 16.26M Dec/2025